Gulle K, Ceri N G, Akpolat M, Arasli M, Demirci B
Bulent Ecevit University, Medical Faculty, Department of Histology and Embryology, Zonguldak, Turkey.
Adnan Menderes University, Medical Faculty, Department of Anatomy, Aydin, Turkey.
Histol Histopathol. 2014 Oct;29(10):1305-13. doi: 10.14670/HH-29.1305. Epub 2014 Apr 14.
This study was designed to investigate the effects of Dexpanthenol (Dxp) on liver and pancreas histology and cytokine levels in streptozotocine (STZ)-induced diabetic rats. Twenty-four Wistar albino male rats were divided into four groups: control, Dxp, STZ-induced diabetic (STZ) and diabetic treatment with Dexpanthenol (STZ-Dxp) groups. Experimental diabetes was induced by single dose STZ (50 mg/kg) intraperitoneally (i.p.). After administration of STZ, the STZ-Dxp group began to receive a 300 mg/kg/day i.p. dose of Dxp for 6 weeks. Liver and pancreas tissues of the control group were in normal morphology. Liver tissue of STZ group showed vacuolisation of hepatocytes in the liver parenchyma with enlargement of sinusoidal spaces and increasing amounts of connective tissue in the portal area. Pancreatic section of STZ group displayed β-cells with of cytoplasmic mass, reduction of islet size, and atrophy. The STZ-Dxp group that received Dxp treatment exhibit partially normal hepatic parenchyma. Histochemical examinations revealed that the diabetes-induced glycogen depletion markedly improved with the Dxp treatment (p⟨0.001). The severity of degenerative alteration was lessened by Dxp supplementation in the STZ-Dxp group. Induction of STZ presented a significant increase both in interleukin-1α (IL-1α) (p=0.033) and monocyte chemotactic protein-1 (MCP-1) (p=0.011) levels, when compared with the control rats. DXP-treated diabetic rats' IL-1α and MCP-1 levels were similar to control value. This evidence suggests that Dxp is effective in reducing STZ-induced, diabetic-related complications and may be beneficial for the treatment of diabetic patients.
本研究旨在探讨右泛醇（Dxp）对链脲佐菌素（STZ）诱导的糖尿病大鼠肝脏和胰腺组织学以及细胞因子水平的影响。将24只Wistar白化雄性大鼠分为四组：对照组、Dxp组、STZ诱导的糖尿病组（STZ组）和用右泛醇治疗的糖尿病组（STZ-Dxp组）。通过腹腔注射（i.p.）单剂量STZ（50 mg/kg）诱导实验性糖尿病。给予STZ后，STZ-Dxp组开始接受每天300 mg/kg腹腔注射剂量的Dxp，持续6周。对照组的肝脏和胰腺组织形态正常。STZ组的肝脏组织显示肝实质内肝细胞空泡化，窦状隙扩大，门管区结缔组织增多。STZ组的胰腺切片显示β细胞胞质减少、胰岛大小减小和萎缩。接受Dxp治疗的STZ-Dxp组肝实质部分恢复正常。组织化学检查显示，Dxp治疗显著改善了糖尿病诱导的糖原耗竭（p<0.001）。在STZ-Dxp组中，补充Dxp减轻了退行性改变的严重程度。与对照大鼠相比，STZ诱导后白细胞介素-1α（IL-1α）（p=0.033）和单核细胞趋化蛋白-1（MCP-1）（p=0.011）水平均显著升高。DXP治疗的糖尿病大鼠的IL-1α和MCP-1水平与对照值相似。这一证据表明，Dxp可有效减少STZ诱导的糖尿病相关并发症，可能对糖尿病患者的治疗有益。
